RENOVORX INC (RNXT) Stock Fundamental Analysis

NASDAQ:RNXT • US75989R1077

0.98 USD
+0.05 (+5%)
Last: Feb 17, 2026, 08:00 PM
Fundamental Rating

3

Taking everything into account, RNXT scores 3 out of 10 in our fundamental rating. RNXT was compared to 521 industry peers in the Biotechnology industry. RNXT has a great financial health rating, but its profitability evaluates not so good. RNXT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year RNXT has reported negative net income.
  • In the past year RNXT has reported a negative cash flow from operations.
  • RNXT had negative earnings in each of the past 5 years.
  • RNXT had a negative operating cash flow in each of the past 5 years.
RNXT Yearly Net Income VS EBIT VS OCF VS FCFRNXT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -2M -4M -6M -8M -10M

1.2 Ratios

  • RNXT has a Return On Assets of -99.10%. This is in the lower half of the industry: RNXT underperforms 74.09% of its industry peers.
  • With a Return On Equity value of -137.47%, RNXT is not doing good in the industry: 62.19% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -99.1%
ROE -137.47%
ROIC N/A
ROA(3y)-314.19%
ROA(5y)-236.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RNXT Yearly ROA, ROE, ROICRNXT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

1.3 Margins

  • The Gross Margin of RNXT (67.78%) is better than 81.00% of its industry peers.
  • RNXT does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 67.78%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RNXT Yearly Profit, Operating, Gross MarginsRNXT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -5K -10K -15K -20K -25K

7

2. Health

2.1 Basic Checks

  • RNXT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for RNXT has been increased compared to 1 year ago.
  • The number of shares outstanding for RNXT has been increased compared to 5 years ago.
  • There is no outstanding debt for RNXT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
RNXT Yearly Shares OutstandingRNXT Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
RNXT Yearly Total Debt VS Total AssetsRNXT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 5M 10M 15M

2.2 Solvency

  • RNXT has an Altman-Z score of -3.11. This is a bad value and indicates that RNXT is not financially healthy and even has some risk of bankruptcy.
  • With a Altman-Z score value of -3.11, RNXT perfoms like the industry average, outperforming 46.83% of the companies in the same industry.
  • There is no outstanding debt for RNXT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.11
ROIC/WACCN/A
WACC8.68%
RNXT Yearly LT Debt VS Equity VS FCFRNXT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 5M -5M 10M -10M 15M

2.3 Liquidity

  • A Current Ratio of 5.83 indicates that RNXT has no problem at all paying its short term obligations.
  • RNXT's Current ratio of 5.83 is fine compared to the rest of the industry. RNXT outperforms 61.42% of its industry peers.
  • A Quick Ratio of 5.68 indicates that RNXT has no problem at all paying its short term obligations.
  • The Quick ratio of RNXT (5.68) is better than 61.42% of its industry peers.
Industry RankSector Rank
Current Ratio 5.83
Quick Ratio 5.68
RNXT Yearly Current Assets VS Current LiabilitesRNXT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 5M 10M 15M

1

3. Growth

3.1 Past

  • RNXT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.21%, which is quite impressive.
EPS 1Y (TTM)36.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • RNXT is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 35.17% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y18.4%
EPS Next 2Y7.87%
EPS Next 3Y23.26%
EPS Next 5Y35.17%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RNXT Yearly Revenue VS EstimatesRNXT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M
RNXT Yearly EPS VS EstimatesRNXT Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 1 -1 2

1

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RNXT. In the last year negative earnings were reported.
  • Also next year RNXT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RNXT Price Earnings VS Forward Price EarningsRNXT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RNXT Per share dataRNXT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.1 -0.1 0.2 -0.2 -0.3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RNXT's earnings are expected to grow with 23.26% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y7.87%
EPS Next 3Y23.26%

0

5. Dividend

5.1 Amount

  • No dividends for RNXT!.
Industry RankSector Rank
Dividend Yield 0%

RENOVORX INC

NASDAQ:RNXT (2/17/2026, 8:00:02 PM)

0.98

+0.05 (+5%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)03-30
Inst Owners14.2%
Inst Owner Change-18.33%
Ins Owners4.58%
Ins Owner Change4.65%
Market Cap35.92M
Revenue(TTM)928.00K
Net Income(TTM)-11.11M
Analysts81.82
Price Target6.22 (534.69%)
Short Float %1.7%
Short Ratio2.2
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)4.84%
Min EPS beat(2)1.96%
Max EPS beat(2)7.73%
EPS beat(4)3
Avg EPS beat(4)-1.05%
Min EPS beat(4)-15.86%
Max EPS beat(4)7.73%
EPS beat(8)6
Avg EPS beat(8)8.57%
EPS beat(12)8
Avg EPS beat(12)6.38%
EPS beat(16)11
Avg EPS beat(16)4.26%
Revenue beat(2)1
Avg Revenue beat(2)-5.08%
Min Revenue beat(2)-35.66%
Max Revenue beat(2)25.5%
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)8.44%
PT rev (3m)8.44%
EPS NQ rev (1m)0.61%
EPS NQ rev (3m)3.53%
EPS NY rev (1m)0%
EPS NY rev (3m)2.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-3.34%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 38.7
P/FCF N/A
P/OCF N/A
P/B 4.45
P/tB 4.45
EV/EBITDA N/A
EPS(TTM)-0.37
EYN/A
EPS(NY)-0.33
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0.03
BVpS0.22
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -99.1%
ROE -137.47%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 67.78%
FCFM N/A
ROA(3y)-314.19%
ROA(5y)-236.06%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.08
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.83
Quick Ratio 5.68
Altman-Z -3.11
F-Score5
WACC8.68%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.21%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%20%
EPS Next Y18.4%
EPS Next 2Y7.87%
EPS Next 3Y23.26%
EPS Next 5Y35.17%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-14.88%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-5.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-4.98%
OCF growth 3YN/A
OCF growth 5YN/A

RENOVORX INC / RNXT FAQ

What is the ChartMill fundamental rating of RENOVORX INC (RNXT) stock?

ChartMill assigns a fundamental rating of 3 / 10 to RNXT.


What is the valuation status for RNXT stock?

ChartMill assigns a valuation rating of 1 / 10 to RENOVORX INC (RNXT). This can be considered as Overvalued.


What is the profitability of RNXT stock?

RENOVORX INC (RNXT) has a profitability rating of 1 / 10.


What is the earnings growth outlook for RENOVORX INC?

The Earnings per Share (EPS) of RENOVORX INC (RNXT) is expected to grow by 18.4% in the next year.